

1 **Patterned progression of gut microbiota**
2 **associated with necrotizing enterocolitis**
3 **and late onset sepsis in preterm infants: a**
4 **prospective study in a Chinese neonatal**
5 **intensive care unit**

6 **Jiayi Liu¹, Yuqing Li², Yi Feng³, Liya Pan⁴, Zhoulonglong Xie⁵, Zhilong**
7 **Yan⁶, Li Zhang⁷, Mingkun Li⁸, Jianhua Zhao⁹, Jianhua Sun¹⁰, and Li**
8 **Hong¹¹**

9 ¹**Department of Clinical Nutrition, Shanghai Children's Medical Center, School of**
10 **Medicine Shanghai Jiao Tong University, Shanghai, China**

11 ²**Department of Clinical Nutrition, Shanghai Children's Medical Center, School of**
12 **Medicine Shanghai Jiao Tong University, Shanghai, China**

13 ³**Department of Clinical Nutrition, Shanghai Children's Medical Center, School of**
14 **Medicine Shanghai Jiao Tong University, Shanghai, China**

15 ⁴**Department of Clinical Nutrition, Shanghai Children's Medical Center, School of**
16 **Medicine Shanghai Jiao Tong University, Shanghai, China**

17 ⁵**Department of Surgery, Shanghai Children's Medical Center, School of Medicine**
18 **Shanghai Jiao Tong University, Shanghai, China**

19 ⁶**Department of Surgery, Shanghai Children's Medical Center, School of Medicine**
20 **Shanghai Jiao Tong University, Shanghai, China**

21 ⁷**Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics,**
22 **China Academy of Science, Beijing, China**

23 ⁸**Key Laboratory of Genomic and Precision Medicine, Beijing Institute of**
24 **Genomics, China Academy of Science, Beijing, China; Center for Excellence in Animal**
25 **Evolution and Genetics, Chinese Academy of Sciences, Kunming, China**

26 ⁹**Shanghai Majorbio Bio-Pharm Technology Co., Ltd, Shanghai, China**

27 ¹⁰**Department of Neonatology, Shanghai Children's Medical Center, School of Medicine**
28 **Shanghai Jiao Tong University, Shanghai, China**

29 ¹¹**Department of Clinical Nutrition, Shanghai Children's Medical Center, School of**
30 **Medicine Shanghai Jiao Tong University, Shanghai, China**

31 Corresponding author:

32 Li Hong¹¹

33 Email address: hongli@scmc.com.cn

34 **ABSTRACT**

Necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) are two common premature birth complications with high morbidity and mortality. Recent studies in Europe and America have linked gut microbiota dysbiosis to their etiology. However, similar studies in Asian populations remain scant. In this pilot study, we profiled gut microbiota of 24 Chinese preterm infants from birth till death or discharge from NICU. Four of them developed NEC and three developed LOS. Unexpectedly, we detected highly-diversified microbiota with similar compositions in all patients shortly after birth. However, as patients aged, the microbial diversities in case groups differed significantly from that of the control group. These differences emerged after the third day of life and persisted throughout the courses of both NEC and LOS. Using a Zero-Inflated Beta Regression Model with Random Effects (ZIBR) we detected higher *Bacillus* ($p = 0.032$) and *Solibacillus* ($p = 0.047$) before the onset of NEC and LOS. During NEC progression, *Enterococcus*, *Streptococcus* and *Peptoclostridium* were the dominant genera; *Klebsiella* was the only dominant genus during LOS progression and was correspondent to the diagnostic hemoculture results. These results warrant further studies to identify causative microbial patterns and underlying mechanisms.

INTRODUCTION

The gut microbiota is a key contributor to human health. Imbalance of the microbial community, termed dysbiosis, is associated with various diseases, such as obesity and diabetes (Bouter et al., 2017; Rosenbaum et al., 2015; Winer et al., 2016; Cani, 2019; Zmora et al., 2019), immunity related diseases (Vogelzang et al., 2018; Pronovost and Hsiao, 2019; Vatanen et al., 2016), neurodevelopmental disorders (Sampson and Mazmanian, 2015; Pronovost and Hsiao, 2019), cardiovascular diseases (Tang et al., 2017; Jie et al., 2017; Jonsson and Bäckhed, 2017) and cancers (Gagliani et al., 2014; Irrazábal et al., 2014; Sears and Garrett, 2014).

The microbiota in newborn infants undergoes dynamic changes in composition, abundance and diversity before reaching homeostasis at around three years of age (Yatsunen et al., 2012; Bäckhed et al., 2015; Stewart et al., 2018). Temporal colonization pattern of the intestinal microbiota during early stages of life may have important contribution to the long term health of an individual. Early life microbiota disruption had been associated with the development of metabolic and immunological diseases such as Type I diabetes (Giongo et al., 2011; Vatanen et al., 2018), asthma (Stokholm et al., 2018) and allergies (Madan et al., 2012a; Savage et al., 2018).

In preterm infants, common medical practices including Cesarean delivery, formula feeding, sterile incubator nursing and extensive use of broad-spectrum antibiotics may limit the normal microbiota acquisition and development (La Rosa et al., 2014; Shin et al., 2015; Deweerdt, 2018). Resultant abnormal microbiota colonization in the gut may then contribute complications such as necrotizing enterocolitis (NEC) and late onset sepsis (LOS) (Sharon et al., 2015; Cernada et al., 2016).

Necrotizing enterocolitis is characterized by rapid ischemic necrosis of intestinal mucosa, resulting in high morbidity (2% - 7%) and mortality (15% - 30%) (Neu and Walker, 2011; Stoll et al., 2015). Its etiology remains largely unknown and likely to be multi-factorial. Previous studies in European and American countries have associated microbial dysbiosis to NEC onset. Reduction in microbiota diversity and unusual species colonization were observed in NEC patients (Jacquot et al., 2011; Warner et al., 2016). No causative species have been identified so far. However, increase in Proteobacteria phyla and decrease in Firmicutes were observed before NEC onset (Mai et al., 2011; Zhou et al., 2015). In addition, blooming of *Gammaproteobacteria* and under-representation of *Negativicutes* were associated with disease progression (Warner et al., 2016).

Late onset sepsis (LOS) is another common life-threatening disease for preterm infants. It is commonly defined as a systemic infection with isolation of a bacterial pathogen from the bloodstream after 72 hours of life (Rao et al., 2016; Pickering et al., 2012). Preterm infants have immature gastrointestinal and immune systems. Therefore, it is easier for pathogenic bacteria or bacterial toxins that can cause systemic inflammation to enter the bloodstream (Schwiertz et al., 2003; Bezirtzoglou et al., 2011; Cernada et al., 2016; Sharon et al., 2015; Korpela et al., 2018), thus making the intestine a potential source of infections and inflammation. Previous studies showed that the LOS patients' gut microbiota was less diversified, and dominated by *Staphylococci* and *Enterobacter* but underrepresented by probiotic *Bifidobacteria* (Madan et al., 2012b; Tarr and Warner, 2016; Stewart et al., 2017; Korpela et al., 2018; Ficara et al., 2018).

NEC and LOS are two major causes of morbidity and mortality in preterm infants worldwide and have been exerting economic burdens on healthcare costs (Johnson et al., 2013, 2014; Mowitz et al., 2018).

88 Although early recognition and treatment regimen has improved clinical outcomes, both diseases still
89 account for morbidities in NICU survivors(Hintz et al., 2005; Zonnenberg et al., 2019; Shah et al., 2015).
90 In China, preterm birth rate is as high as 7.1%(Blencowe et al., 2012) and continuous improvements
91 in neonatal health care have greatly improved the survival of preterm infants. However, the risk of
92 developing NEC and LOS increases as well. Elucidating their pathogenesis and developing preventive
93 strategies would greatly benefit the health of preterm infants. Motivated by this, we carried out this
94 longitudinal pilot study to profile the microbiota of Chinese preterm NEC and LOS patients, with the aim
95 to examine if similar alterations in microbiota correlate with the onset and progression among Chinese
96 patients. Consistent with previous studies in Western countries, we observed lower bacterial diversity
97 among Chinese NEC and LOS patients. In contrast, we found that the Chinese patients in our cohort
98 showed different bacterial compositions.

99 **METHODS**

100 **Ethics**

101 This study was approved by the joint committee of ethics of Shanghai Children's Medical Center, Shanghai
102 Jiao Tong University School of Medicine (SCMCIRB-K2013022). Detailed written informed consent was
103 obtained from parents before enrolment.

104 **Patients**

105 Newly born preterm infants with a gestational age less than 33 weeks and birth weight over 950g were
106 enrolled from Neonatal Intensive Care Unit (NICU) at Shanghai Children's Medical Center from July 2013
107 to December 2014. The exclusion criteria were 1) diagnosed with early-onset sepsis, 2) hepatic diseases,
108 3) renal impairment ($Cr > 88 \mu M$), 4) diagnosed with intestinal obstruction, 5) in foreseeable need of
109 cardiovascular or abdominal surgeries (except for male circumcision or PDA ligation), 6) estimated
110 parenteral support to supply over 50% of daily caloric intake for more than four days, 7) given intravenous
111 antibiotics administration (except prophylactic regimen of cefotaxime, piperacillin-tazobactam and/or
112 metronidazole), 8) history of oral antibiotics administration, 9) grossly bloody stools at admission, and
113 10) over five days old.

114 NEC cases were defined as infants who met the criteria for Stage II and Stage III NEC diagnosis(Bell
115 et al., 1978), including radiographic intestinal dilation, ileus, pneumatosis intestinalis, and/or absent bowel
116 sounds with or without abdominal tenderness, and/or mild metabolic acidosis and thrombocytopenia. An
117 LOS case was defined if an infant 1) had a positive hemoculture or other suspicious loci of infection after
118 72 hours of life, or 2) presented with septic signs/symptoms reviewed and diagnosed independently by at
119 least two neonatologists, and had been responding well with advanced antibiotics (e.g., Meropenem) after
120 diagnosis. Infants with no infectious complications were regarded as controls.

121 **Sample collection and handling**

122 Fecal sample collection started from neonatal meconium until death or discharge, whichever came first.
123 Although we intended to collect fecal samples on a daily basis, due to working shifts and flexible clinical
124 scheduling, we set seven days as the maximum interval between two collections from every infant. Every
125 sample was collected from infants' diaper with a sterile spatula into cryogenic vials within 30 minutes of
126 defecation. Then the sample was immediately placed on dry ice and stored at $-80^{\circ}C$ within 30 minutes
127 without additives. All samples were collected and stored before knowing the diagnosis of respective
128 patients.

129 **DNA extraction and quality control amplification and 16s rRNA gene sequencing**

130 Microbial genomic DNA was isolated from each fecal specimen using the E.Z.N.A.® Soil DNA Kit
131 (Omega Bio-Tek, Norcross, GA, U.S.) according to manufacturer's protocols. The concentration and
132 purity of the DNA were determined by NanoDrop 2000 UV-vis spectrophotometer (Thermo Scientific,
133 Wilmington, USA), and the DNA quality was checked by 1% agarose gel electrophoresis.

134 **Broad-range PCR and High-throughput Sequencing of 16s rRNA gene amplicons**

135 The V3-V4 hypervariable regions of the bacterial 16S rRNA gene were amplified by PCR from each
136 sample using bacterialarchaeal primers 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R (5'-
137 GGACTACHVGG GTWTCTAAT-3') using thermocycler PCR system (GeneAmp 9700, ABI, USA). The

138 PCR reactions were as follows: 3 min of denaturation at 95 °C, 27 cycles of 30 s at 95 °C, 30 s annealing
 139 at 55 °C and 45 s elongation at 72 °C, and a final extension at 72 °C for 10 min. The PCR reactions were
 140 performed in triplicate, with each 20 µL mixture containing 4 µL 5X FastPfu Buffer, 2 µL 2.5 mM dNTPs,
 141 0.8 µL of each primer (5 µM), 0.4 µL FastPfu Polymerase (TransGen Biotech, Beijing, China) and 10
 142 ng template DNA. PCR products were separated from impurities and genomic DNA by running in 2%
 143 agarose gels. The PCR bands were further purified using the AxyPrep DNA Gel Extraction Kit (Axygen
 144 Biosciences, Union City, CA, USA), and quantified using QuantiFluor™-ST (Promega, USA) according
 145 to the manufacturer's protocols. Equimolar amounts of purified amplicons were pooled and paired ended
 146 sequenced (2 x 300) on an Illumina MiSeq platform (Illumina, San Diego, USA) according to the standard
 147 protocols of Majorbio Bio-Pharm Technology Co. Ltd. (Shanghai, China). The reads were de-multiplexed
 148 using the Illumina software and separate FASTQ files were generated for each specimen and deposited to
 149 the Sequence Read Archive NCBI under the BioProject accession PRJNA470548. Another public archive
 150 repository is available at figshare doi: 10.6084/m9.figshare.7205102

151 **Raw Data Processing**

152 Raw data was processed according to the standard protocols provided by Majorbio Bio-Pharm Tech-
 153 nology Co. Ltd. (Shanghai, China) as previously described(Liu et al., 2018; Wang et al., 2018). Raw
 154 sequencing data was first de-multiplexed. Sequence reads were then subjected to quality filtering utilizing
 155 Trimmomatic software(Bolger et al., 2014) and were truncated at any site with an Phred score <20 over a
 156 50bp-sized window. Barcode matching with the primer mismatch from 0 to 2 nucleotides was adopted and
 157 reads containing ambiguous characters were removed. After trimming, FLASH(Fast Length Adjustment
 158 of Short Read)(Magoč and Salzberg, 2011), a read pre-processing software, assembled and merged the
 159 paired-end reads from fragments and generated >10 bp overlapped, with the dead match ratio of 0.2.
 160 Unassembled reads were discarded. From the 192 fecal samples sequenced, a total of 7,472,400 optimized
 161 V3-V4 tags of 16S rRNA gene sequences were generated(Table S1).

162 To unbiasedly compare all the samples at the same sequencing depth, the "sub.sample" command
 163 of mothur program(version1.30.1)(Schloss et al., 2009) was used for normalization to the smallest
 164 sample size. Chimera was detected and removed by UCHIME Algorithm. The effective reads were
 165 then sorted by cluster size and processed using Operational Taxonomic Units (OTUs) with 97% simi-
 166 larity cutoff UPARSE-OTU algorithm (implementing "cluster_otus" command)(Edgar, 2013) in USE-
 167 ARCH(v10)(UPARSE version 7.1). The taxonomy of each 16S rRNA gene sequence was analyzed by
 168 RDP Classifier algorithm(Wang et al., 2007) against the Silva (SSU128) 16S rRNA database(Quast et al.,
 169 2012) using confidence threshold of 70%. Each sequence was assigned the taxonomy by QIIME(Caporaso
 170 et al., 2010). The representative sequences were allocated phylogenetically down to the domain, phylum,
 171 class, order, family, and genus levels(Table S2). The relative abundance of a given taxonomic group was
 172 calculated as the percentage of assigned sequences over total sequences.

173 Within-sample diversity(alpha diversity), including Shannon index and observed species richness
 174 (Sobs), were obtained using the "summary.single" command of mothur program(version1.30.1)(Schloss
 175 et al., 2009). Between-sample diversity(beta diversity) was obtained by calculating weighted UniFrac
 176 distances between samples.

177 **Statistical and Bioinformatics Analyses**

178 ***Demographics and Clinical Sample comparisons***

179 Kruskal-Wallis test and Wilcoxon rank-sum test were used to identify statistically significant differences in
 180 continuous variables, including gestational age, birth weight, age at diagnosis and length of hospitalization.
 181 The χ^2 , or Fisher's exact test was used to identify differences in gender composition. α level was
 182 considered 0.05 for all statistical tests. Other statistical tests not involving microbiome 16S rRNA
 183 sequencing data were performed using "stats" package in R(v.3.5.1).

184 ***Microbiota and Bioinformatics Analyses***

185 **Disease-related Time Interval Definition** Considering that the sampling and disease onset timepoints
 186 for each patient were not perfectly universal, to illustrated the continuous longitudinal and repeated nature
 187 of the sampling and its relationship with onset and progression of diseases, we divided the sampling span
 188 into 7 time intervals:

- 189 1. early post-partum(EPP): within 3 days after birth

2. early pre-onset(EPO): from the end of EPP to at least four days before disease onset
3. late pre-onset(LPO): from the end of EPO to the start of onset; for control group patients, the equivalent onset time is set at 16 days of life, as is the average diagnosis age of NEC and LOS groups.
4. early disease(ED): first third interval of whole disease span; for the control group, the equivalent ED interval is from the day 16 to discharge.
5. middle disease(MD): second third interval of whole disease span
6. late disease(LD): last third interval of whole disease span
7. post disease(PD): from the end of disease to discharge time-point

Modeling Strategies for Comparisons To compare the dynamics of microbiota diversity and relative taxonomic abundance preceding the disease, we applied the EPP, EPO, LPO and ED interval among all patients into our model or comparisons.

Diversity Analyses The average of α diversity was calculated if more than two samples from the same patient were available within one analysis interval. Kruskal Wallis tests were used to compare the differences of overall alpha diversity differences. The MannWhitney U test was then applied to compare two adjacent time intervals. Differences in alpha diversity over time were analyzed by a two-way repeated measures ANOVA, with time interval (EPP, EPO, LPO, ED, MD, LD, PD) as a within-subject factor and group (NEC, LOS, control) as a between-subject factor.

Taxonomic Comparisons The average of each genus relative abundances were calculated only if more than two data points from the same patient were available. Zero-Inflated Beta Regression Model with Random Effects (ZIBR) and Linear Mixed-effects Model (LME) were used to test the association between OTU relative abundance and clinical covariates (diseases-related time intervals) for longitudinal microbiome data (Chen and Li, 2016). *ZIBR* and *nlme*(Pinheiro et al., 2018) R packages were utilized for each model.

Scripts and Figures Archiving

Figures were generated with the "*ggpubr*"(Kassambara, 2017), "*ggplot2*"(Wickham, 2016) and "*ggsci*"(Xiao, 2018) packages using R(v.3.5.1). RScripts for modeling and figures plotting, input and output files, figures are available at our github repository.

RESULTS

Patients characteristics

From July 2013 to December 2014, a total of 130 preterm infants admitted to the neonatal intensive care unit (NICU) of Shanghai Children's Medical Center met the criteria of our study and a total of 1698 samples were collected. 192 fecal samples from 24 well-sampled preterm infants were sequenced. Four subsequently developed NEC (2 in stage IIA and 2 in stage IIB) and three developed LOS (2 with positive hemoculture of *Klebsiella pneumoniae*; the other 1 was diagnosed upon sepsis-related signs and symptoms, lab test of white blood cells >20 cells/microL and her effective reaction to vancomycin). The remaining 17 served as matched controls (Figure1, Table S3). Fecal samples were collected between days 1 and 69 of life. Numbers of samples collected and interval of sampling varied among patients but met our preset criteria of less than 7 days between sampling. The average number of sample collected for NEC, LOS and control patients was 11, 14 and 6 respectively. Number of samples per patient was higher in the NEC and LOS groups because the severity of the disease required longer hospitalization ($p = 0.046$).

All 24 infants profiled were delivered by Cesarean section, fed on infant formula and prescribed with prophylactic antibiotics regimen (cefotaxime, piperacillin-tazobactam and/or metronidazole) right after they were admitted to our NICU. No infant was prescribed probiotics during the study. There was no significant difference in gestational age ($p = 0.074$), birth weight ($p = 0.111$) or gender proportions ($p = 0.822$) among the three groups. The average age at diagnosis for both disease groups was 16 days and there was no statistical difference between the groups ($p = 0.629$) (Table 1). Therefore, we assigned day 16 to discharge as early disease interval, day 4-8 as early pre-onset interval and day 9-15 as late pre-onset interval for the control group.

Longitudinal Microbiome Diversity of NEC and LOS patients

To get an overview of gut microbiota in patients, we analyzed the microbial richness of the NEC and LOS patients over time. Similar to the control group, the case groups showed a decreasing trend in observed species (Sobs) from the early post-partum stage (EPP) to early disease (ED) stage (Fig2 (A) control group, $p < 0.01$; (B) NEC group, $p = 0.044$; (C) LOS group, $p = 0.013$; Dataset S1, Sheet "Sobs" two way RM ANOVA, $p < 0.0001$). The greatest decline in sobs was from early pre-onset (EPO) to late pre-onset (LPO). However, the decrease in the disease groups was less significant than the control group (control group $p = 0.0004$, NEC group $p = 0.18$, LOS group $p = 0.066$). The Sobs then stabilized from LPO onward with no significant difference between adjacent time intervals.

Next, we analyzed gut microbiome evenness over time. Similar to Sobs, the Shannon indices decreased significantly from early post-partum (EPP) to early disease (ED) stage (Fig2(A) control group 2.768 to 1.004, $p = 0.04$; (B) NEC group, 3.141 to 0.578, $p = 0.01$; (C) LOS group, 2.641 to 0.470, $p = 0.01$).

Two way RM ANOVA showed significant Shannon index divergent among three groups before disease onset (Dataset S1, sheet "Shannon", EPP to ED, $p = 0.0017$). Moreover, during early disease stage, the Shannon indices were different among three groups (Fig4, facet "early disease", $p = 0.0037$), suggesting that microbiota distortion may precede NEC and LOS onset. As diseases progressed, the NEC group differed significantly with the LOS group during middle disease interval but insignificantly during late disease interval (Fig4 facet "middle disease", $p = 0.034$; facet "late disease", $p = 0.750$). Upon alleviation of both diseases, the Shannon indices rose back to the early pre-onset levels (Fig3 (B) NEC group. early pre-onset at 1.925 vs. post disease at 1.320, $p = 0.79$; (C) LOS group, early pre-onset at 2.473 vs. post disease at 1.463, $p = 0.16$).

Kinetics of Microbiome Composition

To compare the beta-diversity of the three groups over time, we applied Principal Component Analysis (PCoA) to weighted UniFrac distance matrix. Bacterial composition of three groups during early post-partum interval were the most similar compared with other time intervals, with the first principal coordinates accounted for 33.01% (Fig5 (A)). Then beta diversity continued to separate from one another. The first principal coordinate one (PC1) increased from 33.01% at early post-partum to 35.23% at early pre-onset stage, 38.36% at late-onset stage and eventually reaching 42.32% at early disease stage (Fig5 (B) to (D)). This continuous increase in beta-diversity suggested that the phylogenetic composition of the patients' microbiome started to deviate from the control group before the onset of diseases. As diseases progressed, the phylogenetic similarity between the NEC and the LOS disease groups diverged further and peaked at 59.53% in middle disease stage then decreased gradually to 42.8% at post disease stage (Fig5 (E) to (G)). This trend in phylogenetic dissimilarity suggested that the microbiome composition of the NEC and LOS patients might have deviated from normal even before the onset of diseases. In addition, the further separation between the NEC and the LOS groups could be a result of different treatment strategies.

Colonization Trend at Genus Level

In the analyses of intestinal microbiome alpha (Fig2) and beta diversity (Fig3, Fig4), detectable differences were observed among the three groups, especially during transition from LPO to ED stage. This indicated that the microbiota assembly differences between the case groups and control group. To further investigate which microbiota composition was correlated with the onset and/or progression of NEC and LOS, we tracked the longitudinal compositional changes in each genera abundance. We filtered the genus of over 10% relative abundance among all samples and plotted relative abundance over time (Fig6).

At early post-partum stage, all three groups showed high proportion of *Lactococcus*, *Bacillus* and *Pseudomonas*. However, ZIBR model the disease groups showed significantly higher OTUs that matched to *Bacillus* (NEC 15.05% and LOS 15.97% compare to 6.02% of control, $p = 0.032$) and *Solibacillus* (8.88% in NEC and 9.61% in LOS compare to 3.65% of control, $p = 0.047$) from the case groups (Dataset S2). Moreover, *Enterococcus* proportion (Fig6(B), purple area) was much higher in LOS patients (20.72%) than the normal controls (6.66%, Fig6(A), purple area) but almost absent in NEC patients (0.51%) (Fig6(B)). While all three groups showed increases in *Klebsiella* and *Escherichia-Shigella*, and decreases in *Lactococcus* from EPP to ED, the rates of change were different among the three groups. The LOS group exhibited the most drastic changes, with a rapidly increase of *Klebsiella* (from 4.71% to 58.90%), *Escherichia-Shigella* (from 2.02% to 18.16%) and *Streptococcus* (from 1.22% to 12.68%). (Fig6c). Together, these three genus accounted for almost 100% of all bacteria (Fig6(C)). In

addition, *Lactococcus* decreased more rapidly than the other groups, from 24.54% at EPP to 0.94% before LPO (Fig6(C) magenta area).

Besides, increase of *Klebsiella* was the most minimal in NEC patients (Fig6(B) grey area, from 7.17% at EPP to 35.63% at ED). Moreover, a rapid surge of *Enterococcus*, *Staphylococcus* and *Streptococcus* from EPO to ED was only observed in NEC patients (Fig6(B), purple, dark and light blue area).

As disease progressed with medical intervention, genus in case groups underwent another round of drastic changes. Most notably, the fluctuation of *Enterococcus*, *Klebsiella*, *Staphylococcus* and *Peptoclostridium* during the disease stages (Fig6(B) and (C), stage ED to LD), which might be resultant from different healthcare strategies applied in two groups. Interestingly, as patients approached remission, the composition became more balanced, and resembled more to that of the normal control, except for a higher level of *Clostridium*. In summary, relative to patients in the control group, we observed different patterns of temporal alterations in bacterial composition among NEC and LOS patients. Rapid changes in relative abundance of certain genera were revealed as early as early pre-onset of stages and were the most notable in LOS patients.

DISCUSSION

In this pilot study, we intend to investigate the etiopathology of NEC and LOS in Chinese preterm infants from the perspective of intestinal microbiota. We profiled the gut microbiome of NEC and LOS preterm infants from birth to death or discharge. Some of our findings are similar to previous larger scale studies. Mainly, infants who developed NEC or LOS exhibit a different gut microbiota colonization pattern relative to the controls. Case groups showed decline in diversity, although to different extent. Moreover, NEC and LOS infants' intestines were prone to harbor potential pathogens prior to and after disease onset, such as *Enterococcus*, *Staphylococcus*, *Peptoclostridium* and *Streptococcus*. There were also findings unique to this study will be discussed in the following paragraphs.

To our knowledge, few studies have analyzed stool bacterial alpha diversity in preterm infants as early as three days after birth. Unexpectedly, within three days after birth (i.e. early post-partum interval), the bacterial diversity of all three groups was the highest compared to the following intervals. At this point, we do not know if this high bacterial richness and evenness within three days of life are is universal. More data, especially from other countries, are needed to support this finding. After three days, the microbial alpha diversity exhibited a declining trend in both disease groups and the control group. The number of colonized species (sobs index) during this interval, in line with previous works(Mai et al., 2011, 2013), remained similar before disease onset in both case and control groups, suggesting a minor role of bacterial richness in the disease onset. Besides, a rapid decline in alpha diversity during the pre-onset stages was observed. This could be the resultant from the standardized antibiotic regimen right after admission into our NICU. However, previous studies showed that the pervasive effect of antibiotics in reducing richness and evenness arose only at 1 week to 2 months after administration(DiGiulio et al., 2008; Dethlefsen and Relman, 2011; Fouhy et al., 2012; Greenwood et al., 2014; Tanaka et al., 2009). Thus, more research is needed to identify if additional factor(s) is involved in this rapid decline.

The role of empiric prophylactic antibiotics in NEC or LOS is controversial. In animal models, antibiotics eliminating Gram-negative bacteria enhance gut function and diminish mucosal injury to the bowel thus preventing necrotizing enterocolitis or bacterial leakage into the bloodstream(Carlisle et al., 2011; Jensen et al., 2013; Birck et al., 2015). In clinical practices, broad-spectrum antibiotics (the most commonly prescribed medicine in the NICU) are recommended to empirically prevent and treat both NEC and LOS(Bury and Tudehope, 2001; Brook, 2008; Kimberlin et al., 2018). However, antibiotics could further result in microbiome dysbiosis therefore increasing the risk of developing these diseases and exacerbating the severity (Gibson et al., 2015; Kuppala et al., 2011; Martinez et al., 2017; Cantey et al., 2018). Our results showed limited differences in bacterial diversity and composition between two case groups and the control group despite continuously antibiotics administration. Although our results are in line with the dysbiotic effect of antibiotics, there was not enough evidence to support whether antibiotics per se induced or prevented NEC and LOS. Further studies are needed to confirm the causative relationships.

Furthermore, microbiota beta-diversity, which measures the phylogenetic similarity, drifted away continuously among three groups before the onset of both disease. These findings were inconsistent with a previous study where the microbiota of NEC patients were shown to be similar to that of the healthy controls at three days before onset(Mai et al., 2011). With regards to the LOS patients, it is

also inconsistent with previous study where similar microbiota diversity was observed in LOS patients during the disease and 72 hours before onset(Mai et al., 2013). These discrepancies could be a result of differences in collection time points or differences in patients' demographics. Further studies are necessary to address these issues. As disease progressed, the beta-diversity of the NEC group and the LOS group separated further but converged again when diseases were alleviated. The exact cause of this divergence was not clear. It could be related to different treatment strategies or some intrinsic pathophysiology differences between the two diseases. Further studies should provide more insight.

In addition to bacterial diversity, we also tracked longitudinal changes in composition at genus level by plotting the relative abundance over time. Overall, the control group exhibited more stable microbiota assembly, without drastic fluctuation in genus abundance and with less dominance of facultative anaerobes such as *Enterococcus* and *Staphylococcus*(Gibson et al., 2015; La Rosa et al., 2014; Grier et al., 2017). Based on our ZIBR model, an over-represented *Bacillus* and *Solibacillus* were detected during the pre-onset stages in case groups. However, both genus diminished after disease onset suggesting that the initial microbiota composition in preterms might contribute to their future health outcomes. Previous studies also observed a surge in Proteobacteria phyla(Mai et al., 2013, 2011) preceding LOS and NEC onset. In line with this, LOS patients in our cohort were also characterized by higher abundance of *Klebsiella* in their intestinal communities. On the contrary, NEC infants presented overgrowth of *Streptococcus* and *Staphylococcus* (both belong to *Firmicutes* phyla) before disease onset. Further work is warranted to identify specific genera and trends in association with the onset of NEC and/or LOS.

Diarrhea is one of the typical symptoms in NEC patients and *Peptoclostridium* is conventionally regarded as a pathogen in hospital-acquired infectious diarrhea(Rodriguez et al., 2016; Pereira et al., 2016). In our study, we firstly identified a transient blossom of *Peptoclostridium* in late NEC stage, possibly explaining the mechanism of diarrhea symptom in necrotizing enterocolitis. Moreover, mucosal-adhering bacteria such as *Enterococcus* and *Streptococcus* were highly represented in pediatric enterocolitis(Normann et al., 2013; Zhou et al., 2016). Consistent with this, NEC patients from our cohort harbored increasingly abundant *Enterococcus* during disease stage.

In contrast, the composition of our LOS patient sample was very different from previous studies. Although previous studies have identified *Enterobacteria* and *Staphylococcus* were the most prevalent genera(Stewart et al., 2017; Mai et al., 2013), *Klebsiella* was the most dominated genus in our LOS patients' intestines. Together with the diagnostic hemoculture results which identified *Klebsiella* as the dominant genus in two of the three LOS patients, our findings support the hypothesis that neonatal LOS is frequently caused by organisms that translocate from the intestinal tract. In addition, *Klebsiella pneumoniae* is one of the most common causes of sepsis in preterm patients in our hospital (JL and LH personal observation), suggesting that the most dominant gut bacteria in infant may be more specific to the environment.

Another notable point in our cohort was almost absent *Bifidobacteria*, which is an anaerobic, milk-degrading genus(Gomez-Gallego et al., 2016) thus commonly detected among breast-fed infants(Murphy et al., 2017). We speculate this extremely low level in our cohort is due to a lack of breast-feeding in the sterile hospital environment, being nurtured in the sterile NICU environment, continuous administration of antibiotics or the combinations of the above. Although *Bifidobacteria* has been generally considered a probiotic that serves to protect neonates against necrotizing enterocolitis and systemic infection(Nakayama et al., 2003; Khodayar-Pardo et al., 2014; Hermansson et al., 2019), recent randomized controlled trials are showing paradoxical results(Hays et al., 2016; Singh et al., 2019). Further studies on probiotics in optimizing microbiome in preterm infants should evaluate its efficacy.

This study was limited to only one hospital in one specific region (Shanghai) in China so how far these findings can be extrapolated remains to be determined. In addition, our sample size was relatively small since both diseases are rare(Neu and Walker, 2011; Cohen-Wolkowicz et al., 2009). Among the 1148 preterm infants admitted within July 2013 to December 2014, only five developed NEC and seven developed LOS. Nevertheless, this pilot study has provided essential information about NEC and LOS preterm patients within the Chinese population and serves as a starting point for future investigation into the etiology and pathogenesis of both disease in the nation.

CONCLUSIONS

In this longitudinal study, we used next generation sequencing to profile microbiota of 24 Chinese preterm infants from birth to discharge. Among them, four developed NEC and three developed LOS. To our

knowledge, this is the first profiling NEC and LOS patients among Asian population. Reduction in intestinal microbiota diversity and divergence of phylogenetic similarity from the control infants over time associated with both NEC and LOS onset. Overgrowth of potentially pathogenic genus *Enterococcus*, *Streptococcus* and *Peptoclostridium* were observed in NEC cases while *Klebsiella* was recognized as the dominant genus in LOS cases. In summary, our findings suggests that both NEC and LOS are dynamic processes involving abnormal microbiota assembly. This study is a starting point for further studying of microbial factors involved in preterm-associated complications in China. Accumulation of more data within China and perhaps from neighboring countries will allow us to build microbial signatures that can assist early diagnosis and development of novel treatment.

ACKNOWLEDGMENTS

We sincerely thank all the patients and their family in supporting this study. We extend our thanks to the medical and research staffs of the Shanghai Children's Medical Center. We also thank Ka Ming Pang, Arin Nam and Christina Meyer for critical reviews of this manuscript.

REFERENCES

- Bäckhed, F., Roswall, J., Peng, Y., Feng, Q., Jia, H., Kovatcheva-Datchary, P., Li, Y., Xia, Y., Xie, H., Zhong, H., et al. (2015). Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell host & microbe*, 17(5):690–703.
- Bell, M. J., Ternberg, J. L., Feigin, R. D., Keating, J. P., Marshall, R., Barton, L., and Brotherton, T. (1978). Neonatal necrotizing enterocolitis. therapeutic decisions based upon clinical staging. *Annals of surgery*, 187(1):1.
- Bezirtzoglou, E., Tsiotsias, A., and Welling, G. W. (2011). Microbiota profile in feces of breast-and formula-fed newborns by using fluorescence in situ hybridization (fish). *Anaerobe*, 17(6):478–482.
- Birck, M. M., Nguyen, D. N., Cilieborg, M. S., Kamal, S. S., Nielsen, D. S., Damborg, P., Olsen, J. E., Lauridsen, C., Sangild, P. T., and Thymann, T. (2015). Enteral but not parenteral antibiotics enhance gut function and prevent necrotizing enterocolitis in formula-fed newborn preterm pigs. *American Journal of Physiology-Heart and Circulatory Physiology*.
- Blencowe, H., Cousens, S., Oestergaard, M. Z., Chou, D., Moller, A.-B., Narwal, R., Adler, A., Garcia, C. V., Rohde, S., Say, L., et al. (2012). National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *The Lancet*, 379(9832):2162–2172.
- Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for illumina sequence data. *Bioinformatics*, 30(15):2114–2120.
- Bouter, K. E., van Raalte, D. H., Groen, A. K., and Nieuwdorp, M. (2017). Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. *Gastroenterology*, 152(7):1671–1678.
- Brook, I. (2008). Microbiology and management of neonatal necrotizing enterocolitis. *American journal of perinatology*, 25(02):111–118.
- Bury, R. G. and Tudehope, D. (2001). Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants. *Cochrane Database of Systematic Reviews*, (1).
- Cani, P. D. (2019). Severe obesity and gut microbiota: does bariatric surgery really reset the system? *Gut*, 68(1):5–6.
- Cantey, J. B., Pyle, A. K., Wozniak, P. S., Hynan, L. S., and Sánchez, P. J. (2018). Early antibiotic exposure and adverse outcomes in preterm, very low birth weight infants. *The Journal of pediatrics*, 203:62–67.
- Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Pena, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010). Qiime allows analysis of high-throughput community sequencing data. *Nature methods*, 7(5):335.
- Carlisle, E. M., Poroyko, V., Caplan, M. S., Alverdy, J. A., and Liu, D. (2011). Gram negative bacteria are associated with the early stages of necrotizing enterocolitis. *PloS one*, 6(3):e18084.
- Cernada, M., Bäuerl, C., Serna, E., Collado, M. C., Martínez, G. P., and Vento, M. (2016). Sepsis in preterm infants causes alterations in mucosal gene expression and microbiota profiles compared to non-septic twins. *Scientific Reports*, 6(1):25497.

- Chen, E. Z. and Li, H. (2016). A two-part mixed-effects model for analyzing longitudinal microbiome compositional data. *Bioinformatics*, 32(17):2611–2617.
- Cohen-Wolkowicz, M., Moran, C., Benjamin, D. K., Cotten, C. M., Clark, R. H., Benjamin Jr, D. K., and Smith, P. B. (2009). Early and late onset sepsis in late preterm infants. *The Pediatric infectious disease journal*, 28(12):1052.
- Dethlefsen, L. and Relman, D. A. (2011). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proceedings of the National Academy of Sciences*, 108(Supplement 1):4554–4561.
- Deweerd, S. (2018). How baby’s first microbes could be crucial to future health. *Nature*, 555(7695):S18–S19.
- DiGiulio, D. B., Romero, R., Amogan, H. P., Kusanovic, J. P., Bik, E. M., Gotsch, F., Kim, C. J., Erez, O., Edwin, S., and Relman, D. A. (2008). Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. *PloS one*, 3(8):e3056.
- Edgar, R. C. (2013). Uparse: highly accurate otu sequences from microbial amplicon reads. *Nature methods*, 10(10):996.
- Ficara, M., Pietrella, E., Spada, C., Della Casa Muttini, E., Lucaccioni, L., Iughetti, L., and Berardi, A. (2018). Changes of intestinal microbiota in early life. *The Journal of Maternal-Fetal & Neonatal Medicine*, pages 1–8.
- Fouhy, F., Guinane, C. M., Hussey, S., Wall, R., Ryan, C. A., Dempsey, E. M., Murphy, B., Ross, R. P., Fitzgerald, G. F., Stanton, C., et al. (2012). High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. *Antimicrobial agents and chemotherapy*, 56(11):5811–5820.
- Gagliani, Nicola, Hu, Bo, Huber, Samuel, Elinav, and Richard (2014). The fire within: Microbes inflame tumors. *Cell*, 157(4):776–783.
- Gibson, M. K., Crofts, T. S., and Dantas, G. (2015). Antibiotics and the developing infant gut microbiota and resistance. *Current opinion in microbiology*, 27:51–56.
- Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Novelo, L. L., Casella, G., Drew, J. C., Ilonen, J., Knip, M., Hyöty, H., et al. (2011). Toward defining the autoimmune microbiome for type 1 diabetes. *The ISME journal*, 5(1):82.
- Gomez-Gallego, C., Garcia-Mantrana, I., Salminen, S., and Collado, M. C. (2016). The human milk microbiome and factors influencing its composition and activity. In *Seminars in Fetal and Neonatal Medicine*, volume 21, pages 400–405. Elsevier.
- Greenwood, C., Morrow, A. L., Lagomarcino, A. J., Altaye, M., Taft, D. H., Yu, Z., Newburg, D. S., Ward, D. V., and Schibler, K. R. (2014). Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of enterobacter. *The Journal of pediatrics*, 165(1):23–29.
- Grier, A., Qiu, X., Bandyopadhyay, S., Holden-Wiltse, J., Kessler, H. A., Gill, A. L., Hamilton, B., Huyck, H., Misra, S., Mariani, T. J., et al. (2017). Impact of prematurity and nutrition on the developing gut microbiome and preterm infant growth. *Microbiome*, 5(1):158.
- Hays, S., Jacquot, A., Gauthier, H., Kempf, C., Beissel, A., Pidoux, O., Jumas-Bilak, E., Decullier, E., Lachambre, E., Beck, L., et al. (2016). Probiotics and growth in preterm infants: A randomized controlled trial, premapro study. *Clinical Nutrition*, 35(4):802–811.
- Hermansson, H., Kumar, H., Collado, M. C., Salminen, S., Isolauri, E., and Rautava, S. (2019). Breast milk microbiota is shaped by mode of delivery and intrapartum antibiotic exposure. *Frontiers in nutrition*, 6.
- Hintz, S. R., Kendrick, D. E., Stoll, B. J., Vohr, B. R., Fanaroff, A. A., Donovan, E. F., Poole, W. K., Blakely, M. L., Wright, L., Higgins, R., et al. (2005). Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. *Pediatrics*, 115(3):696–703.
- Irrazábal, T., Belcheva, A., Girardin, S. E., Martin, A., and Philpott, D. J. (2014). The multifaceted role of the intestinal microbiota in colon cancer. *Molecular Cell*, 54(2):309–320.
- Jacquot, A., Neveu, D., Aujoulat, F., Mercier, G., Marchandin, H., Jumas-Bilak, E., and Picaud, J.-C. (2011). Dynamics and clinical evolution of bacterial gut microflora in extremely premature patients. *The Journal of pediatrics*, 158(3):390–396.
- Jensen, M. L., Thymann, T., Cilieborg, M. S., Lykke, M., Mølbak, L., Jensen, B. B., Schmidt, M., Kelly, D., Mulder, I., Burrin, D. G., et al. (2013). Antibiotics modulate intestinal immunity and prevent

508 necrotizing enterocolitis in preterm neonatal piglets. *American Journal of Physiology-Heart and*
509 *Circulatory Physiology*.

510 Jie, Z., Xia, H., Zhong, S. L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., and Zhao, H. (2017).
511 The gut microbiome in atherosclerotic cardiovascular disease. *Nature Communications*, 8(1).

512 Johnson, T. J., Patel, A. L., Bigger, H. R., Engstrom, J. L., and Meier, P. P. (2014). Economic benefits
513 and costs of human milk feedings: a strategy to reduce the risk of prematurity-related morbidities in
514 very-low-birth-weight infants. *Advances in nutrition*, 5(2):207–212.

515 Johnson, T. J., Patel, A. L., Jegier, B. J., Engstrom, J. L., and Meier, P. P. (2013). Cost of morbidities in
516 very low birth weight infants. *The Journal of pediatrics*, 162(2):243–249.

517 Jonsson, A. L. and Bäckhed, F. (2017). Role of gut microbiota in atherosclerosis. *Nature Reviews*
518 *Cardiology*, 14(2):79.

519 Kassambara, A. (2017). ggpubr:“ggplot2” based publication ready plots. r package version 0.1. 6.

520 Khodayar-Pardo, P., Mira-Pascual, L., Collado, M., and Martinez-Costa, C. (2014). Impact of lactation
521 stage, gestational age and mode of delivery on breast milk microbiota. *Journal of Perinatology*,
522 34(8):599.

523 Kimberlin, D. W. et al. (2018). *Red Book: 2018-2021 report of the committee on infectious diseases*.
524 Number Ed. 31. American academy of pediatrics.

525 Korpela, K., Blakstad, E. W., Moltu, S. J., Strømmen, K., Nakstad, B., Rønnestad, A. E., Brække, K.,
526 Iversen, P. O., Drevon, C. A., and Vos, W. (2018). Intestinal microbiota development and gestational
527 age in preterm neonates. *Scientific reports*, 8(1):2453.

528 Kuppala, V. S., Meinzen-Derr, J., Morrow, A. L., and Schibler, K. R. (2011). Prolonged initial empirical
529 antibiotic treatment is associated with adverse outcomes in premature infants. *The Journal of pediatrics*,
530 159(5):720–725.

531 La Rosa, P. S., Warner, B. B., Zhou, Y., Weinstock, G. M., Sodergren, E., Hall-Moore, C. M., Stevens, H. J.,
532 Bennett, W. E., Shaikh, N., Linneman, L. A., et al. (2014). Patterned progression of bacterial populations
533 in the premature infant gut. *Proceedings of the National Academy of Sciences*, 111(34):12522–12527.

534 Liu, Y., Li, J., Jin, Y., Zhao, L., Zhao, F., Feng, J., Li, A., and Wei, Y. (2018). Splenectomy leads
535 to amelioration of altered gut microbiota and metabolome in liver cirrhosis patients. *Frontiers in*
536 *Microbiology*, 9.

537 Madan, J. C., Farzan, S. F., Hibberd, P. L., and Karagas, M. R. (2012a). Normal neonatal microbiome
538 variation in relation to environmental factors, infection and allergy. *Current opinion in pediatrics*,
539 24(6):753.

540 Madan, J. C., Salari, R. C., Saxena, D., Davidson, L., O’toole, G. A., Moore, J. H., Sogin, M. L.,
541 Foster, J. A., Edwards, W. H., Palumbo, P., et al. (2012b). Gut microbial colonisation in premature
542 neonates predicts neonatal sepsis. *Archives of Disease in Childhood-Fetal and Neonatal Edition*,
543 97(6):F456–F462.

544 Magoč, T. and Salzberg, S. L. (2011). Flash: fast length adjustment of short reads to improve genome
545 assemblies. *Bioinformatics*, 27(21):2957–2963.

546 Mai, V., Torrazza, R. M., Ukhanova, M., Wang, X., Sun, Y., Li, N., Shuster, J., Sharma, R., Hudak, M. L.,
547 and Neu, J. (2013). Distortions in development of intestinal microbiota associated with late onset sepsis
548 in preterm infants. *PloS one*, 8(1):e52876.

549 Mai, V., Young, C. M., Ukhanova, M., Wang, X., Sun, Y., Casella, G., Theriaque, D., Li, N., Sharma, R.,
550 Hudak, M., et al. (2011). Fecal microbiota in premature infants prior to necrotizing enterocolitis. *PloS*
551 *one*, 6(6):e20647.

552 Martinez, F. E., Ferri, W. A., Leone, C. R., De Almeida, M. F. B., Guinsburg, R., do Amaral Meneses, J.,
553 do Vale, M. S., Marba, S. T. M., De Carvalho, W. B., de Souza Rugolo, L. M. S., et al. (2017). Early
554 empiric antibiotic use is associated with delayed feeding tolerance in preterm infants: A retrospective
555 analysis. *Journal of pediatric gastroenterology and nutrition*, 65(1):107–110.

556 Mowitz, M. E., Dukhovny, D., and Zupancic, J. A. (2018). The cost of necrotizing enterocolitis in
557 premature infants. In *Seminars in Fetal and Neonatal Medicine*. Elsevier.

558 Murphy, K., Curley, D., O’Callaghan, T. F., O’Shea, C.-A., Dempsey, E. M., O’Toole, P. W., Ross, R. P.,
559 Ryan, C. A., and Stanton, C. (2017). The composition of human milk and infant faecal microbiota over
560 the first three months of life: a pilot study. *Scientific reports*, 7:40597.

561 Nakayama, M., Yajima, M., Hatano, S., Yajima, T., and Kuwata, T. (2003). Intestinal adherent bacteria
562 and bacterial translocation in breast-fed and formula-fed rats in relation to susceptibility to infection.

563 *Pediatric research*, 54(3):364.
 564 Neu, J. and Walker, W. A. (2011). Necrotizing enterocolitis. *New England Journal of Medicine*,
 565 364(3):255–264.
 566 Normann, E., Fahlén, A., Engstrand, L., and Lilja, H. E. (2013). Intestinal microbial profiles in extremely
 567 preterm infants with and without necrotizing enterocolitis. *Acta paediatrica*, 102(2):129–136.
 568 Pereira, F. L., Júnior, C. A. O., Silva, R. O., Dorella, F. A., Carvalho, A. F., Almeida, G. M., Leal, C. A.,
 569 Lobato, F. C., and Figueiredo, H. C. (2016). Complete genome sequence of *peptoclostridium difficile*
 570 strain z31. *Gut pathogens*, 8(1):11.
 571 Pickering, L. K., Baker, C. J., Kimberlin, D. W., et al. (2012). *Red Book, (2012): Report of the Committee*
 572 *on Infectious Diseases*. Am Acad Pediatrics.
 573 Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D., and R Core Team (2018). *nlme: Linear and Nonlinear*
 574 *Mixed Effects Models*. R package version 3.1-137.
 575 Pronovost, G. N. and Hsiao, E. Y. (2019). Perinatal interactions between the microbiome, immunity, and
 576 neurodevelopment. *Immunity*, 50(1):18–36.
 577 Quast, C., Priesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., and Glöckner, F. O.
 578 (2012). The silva ribosomal rna gene database project: improved data processing and web-based tools.
 579 *Nucleic acids research*, 41(D1):D590–D596.
 580 Rao, S. C., Srinivasjois, R., and Moon, K. (2016). One dose per day compared to multiple doses per day
 581 of gentamicin for treatment of suspected or proven sepsis in neonates. *Cochrane database of systematic*
 582 *reviews*, (12).
 583 Rodriguez, C., Van Broeck, J., Taminiau, B., Delmée, M., and Daube, G. (2016). *Clostridium difficile*
 584 *infection: early history, diagnosis and molecular strain typing methods*. *Microbial pathogenesis*,
 585 97:59–78.
 586 Rosenbaum, M., Knight, R., and Leibel, R. L. (2015). The gut microbiota in human energy homeostasis
 587 and obesity. *Trends in Endocrinology & Metabolism*, 26(9):493–501.
 588 Sampson, T. R. and Mazmanian, S. K. (2015). Control of brain development, function, and behavior by
 589 the microbiome. *Cell Host & Microbe*, 17(5):565–576.
 590 Savage, J. H., Lee-Sarwar, K. A., Sordillo, J., Bunyavanich, S., Zhou, Y., O’connor, G., Sandel, M.,
 591 Bacharier, L. B., Zeiger, R., Sodergren, E., et al. (2018). A prospective microbiome-wide association
 592 study of food sensitization and food allergy in early childhood. *Allergy*, 73(1):145–152.
 593 Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A.,
 594 Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009). Introducing mothur: open-source, platform-
 595 independent, community-supported software for describing and comparing microbial communities.
 596 *Applied and environmental microbiology*, 75(23):7537–7541.
 597 Schwertz, A., Gruhl, B., Löbnitz, M., Michel, P., Radke, M., and Blaut, M. (2003). Development of the
 598 intestinal bacterial composition in hospitalized preterm infants in comparison with breast-fed, full-term
 599 infants. *Pediatric research*, 54(3):393.
 600 Sears, C. L. and Garrett, W. S. (2014). Microbes, microbiota, and colon cancer. *Cell Host & Microbe*,
 601 15(3):317–328.
 602 Shah, J., Jefferies, A. L., Yoon, E. W., Lee, S. K., Shah, P. S., Network, C. N., et al. (2015). Risk factors
 603 and outcomes of late-onset bacterial sepsis in preterm neonates born at 32 weeks’ gestation. *American*
 604 *journal of perinatology*, 32(07):675–682.
 605 Sharon, U., Alain, S., Prakesh Kumar, S., David, M., and O’Connor, D. L. (2015). Gut microbiota of the
 606 very-low-birth-weight infant. *Pediatric Research*, 77(1-2):205.
 607 Shin, H., Pei, Z., Martinez, K. A., Rivera-Vinas, J. I., Mendez, K., Cavallin, H., and Dominguez-Bello,
 608 M. G. (2015). The first microbial environment of infants born by c-section: the operating room
 609 microbes. *Microbiome*, 3(1):59.
 610 Singh, B., Shah, P. S., Afifi, J., Simpson, C. D., Mitra, S., Dow, K., and El-Naggar, W. (2019). Probiotics
 611 for preterm infants: A national retrospective cohort study. *Journal of Perinatology*, page 1.
 612 Stewart, C. J., Ajami, N. J., O’Brien, J. L., Hutchinson, D. S., Smith, D. P., Wong, M. C., Ross, M. C.,
 613 Lloyd, R. E., Doddapaneni, H., Metcalf, G. A., et al. (2018). Temporal development of the gut
 614 microbiome in early childhood from the teddy study. *Nature*, 562(7728):583.
 615 Stewart, C. J., Embleton, N. D., Marrs, E. C. L., Smith, D. P., Fofanova, T., Nelson, A., Skeath, T., Perry,
 616 J. D., Petrosino, J. F., and Berrington, J. E. (2017). Longitudinal development of the gut microbiome
 617 and metabolome in preterm neonates with late onset sepsis and healthy controls. *Microbiome*, 5(1):75.

618 Stokholm, J., Blaser, M. J., Thorsen, J., Rasmussen, M. A., Waage, J., Vinding, R. K., Schoos, A.-M. M.,
619 Kunøe, A., Fink, N. R., Chawes, B. L., et al. (2018). Maturation of the gut microbiome and risk of
620 asthma in childhood. *Nature communications*, 9(1):141.

621 Stoll, B. J., Hansen, N. I., Bell, E. F., Walsh, M. C., Carlo, W. A., Shankaran, S., Laptook, A. R., Sánchez,
622 P. J., Van Meurs, K. P., Wyckoff, M., et al. (2015). Trends in care practices, morbidity, and mortality of
623 extremely preterm neonates, 1993–2012. *Jama*, 314(10):1039–1051.

624 Tanaka, S., Kobayashi, T., Songjinda, P., Tateyama, A., Tsubouchi, M., Kiyohara, C., Shirakawa, T.,
625 Sonomoto, K., and Nakayama, J. (2009). Influence of antibiotic exposure in the early postnatal period
626 on the development of intestinal microbiota. *FEMS Immunology & Medical Microbiology*, 56(1):80–87.

627 Tang, W. W., Kitai, T., and Hazen, S. L. (2017). Gut microbiota in cardiovascular health and disease.
628 *Circulation research*, 120(7):1183–1196.

629 Tarr, P. I. and Warner, B. B. (2016). Gut bacteria and late-onset neonatal bloodstream infections in preterm
630 infants. In *Seminars in Fetal and Neonatal Medicine*, volume 21, pages 388–393. Elsevier.

631 Vatanen, T., Franzosa, E. A., Schwager, R., Tripathi, S., Arthur, T. D., Vehik, K., Lernmark, Å., Hagopian,
632 W. A., Rewers, M. J., She, J.-X., et al. (2018). The human gut microbiome in early-onset type 1 diabetes
633 from the teddy study. *Nature*, 562(7728):589.

634 Vatanen, T., Kostic, A., D’Hennezel, E., Siljander, H., Franzosa, E., Yassour, M., Kolde, R., Vlamakis, H.,
635 Arthur, T., and Hämäläinen, A. M. (2016). Variation in microbiome lps immunogenicity contributes to
636 autoimmunity in humans. *Cell*, 165(4):842–853.

637 Vogelzang, A., Guerrini, M. M., Minato, N., and Fagarasan, S. (2018). Microbiota—an amplifier of
638 autoimmunity. *Current opinion in immunology*, 55:15–21.

639 Wang, Q., Garrity, G. M., Tiedje, J. M., and Cole, J. R. (2007). Naive bayesian classifier for rapid
640 assignment of rna sequences into the new bacterial taxonomy. *Applied and environmental microbiology*,
641 73(16):5261–5267.

642 Wang, R., Xiao, Y., Lv, F., Hu, L., Wei, L., Yuan, Z., and Lin, H. (2018). Bacterial community structure
643 and functional potential of rhizosphere soils as influenced by nitrogen addition and bacterial wilt disease
644 under continuous sesame cropping. *Applied Soil Ecology*, 125:117–127.

645 Warner, B. B., Deych, E., Zhou, Y., Hall-Moore, C., Weinstock, G. M., Sodergren, E., Shaikh, N.,
646 Hoffmann, J. A., Linneman, L. A., Hamvas, A., Khanna, G., Rouggy-Nickless, L. C., Ndao, I. M.,
647 Shands, B. A., Escobedo, M., Sullivan, J. E., Radmacher, P. G., Shannon, W. D., and Tarr, P. I. (2016).
648 Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: A prospective
649 case-control study. *The Lancet*, 387(10031):1928–1936.

650 Wickham, H. (2016). *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York.

651 Winer, D. A., Luck, H., Tsai, S., and Winer, S. (2016). The intestinal immune system in obesity and
652 insulin resistance. *Cell metabolism*, 23(3):413–426.

653 Xiao, N. (2018). *ggsci: Scientific Journal and Sci-Fi Themed Color Palettes for 'ggplot2'*. R package
654 version 2.9.

655 Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M.,
656 Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012). Human gut microbiome viewed across
657 age and geography. *nature*, 486(7402):222.

658 Zhou, Y., Chen, H., He, H., Du, Y., Hu, J., Li, Y., Li, Y., Zhou, Y., Wang, H., Chen, Y., et al. (2016).
659 Increased enterococcus faecalis infection is associated with clinically active crohn disease. *Medicine*,
660 95(39).

661 Zhou, Y., Shan, G., Sodergren, E., Weinstock, G., Walker, W. A., and Gregory, K. E. (2015). Longitudinal
662 analysis of the premature infant intestinal microbiome prior to necrotizing enterocolitis: a case-control
663 study. *PloS one*, 10(3):e0118632.

664 Zmora, N., Suez, J., and Elinav, E. (2019). You are what you eat: diet, health and the gut microbiota.
665 *Nature Reviews Gastroenterology & Hepatology*, 16(1):35–56.

666 Zonnenberg, I., van Dijk-Lokkart, E., van den Dungen, F., Vermeulen, R., and van Weissenbruch, M.
667 (2019). Neurodevelopmental outcome at 2 years of age in preterm infants with late-onset sepsis.
668 *European journal of pediatrics*, pages 1–8.